Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Successful treatment of infantile hepatitis B with lamivudine: A case report
Yu-Ting Zhang, Jing Liu, Xiao-Ben Pan, Yi-Dan Gao, Yin-Fei Hu, Li Lin, Hua-Jun Cheng, Gong-Ying Chen
Yu-Ting Zhang, Jing Liu, Xiao-Ben Pan, Yi-Dan Gao, Gong-Ying Chen, Department of Infectious Disease, The Affiliated Hospital of Hangzhou Normal University, Hangzhou 310015, Zhejiang Province, China
Yu-Ting Zhang, Yin-Fei Hu, The Fourth Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang Province, China
Xiao-Ben Pan, Department of Basic Medical Sciences, School of Medicine, Hangzhou Normal University, Hangzhou 310036, Zhejiang Province, China
Li Lin, Gong-Ying Chen, The Clinical Medical College, Hangzhou Normal University, Hangzhou 310036, Zhejiang Province, China
Hua-Jun Cheng, Gong-Ying Chen, Department of Gastroenterology, Yiwu Chouzhou Hospital, Jinhua 322000, Zhejiang Province, China
Author contributions: Zhang YT analyzed the data and wrote the manuscript; Liu J and Pan XB contributed important advice during manuscript preparation; Chen GY as a special expert at Yiwu Chouzhou Hospital, worked part-time there and made the diagnosis and treatment plan together with Cheng HJ; Liu J and Gao YD revised the manuscript; Hu YF and Lin L collected the data and performed the follow-up.
Supported by National Natural Science Foundation of China (General Program), No. 82070610.
Informed consent statement: Informed consent was obtained from the patient's mother.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Gong-Ying Chen, PhD, Chief Physician, Professor, Department of Infectious Disease, The Affiliated Hospital of HangZhou Normal University, No. 126 Wenzhou Road, Gongshu District, Hangzhou 310015, Zhejiang Province, China.
liuxingli0329@163.com
Received: December 12, 2020
Peer-review started: December 12, 2020
First decision: January 27, 2021
Revised: February 8, 2021
Accepted: March 3, 2021
Article in press: March 3, 2021
Published online: May 16, 2021
Processing time: 138 Days and 0.1 Hours
BACKGROUND
How to treat infantile hepatitis B virus (HBV) infection remains a controversial issue. The nucleoside analogue lamivudine (LAM) has been approved to treat children (2 to 17 years old) with chronic hepatitis B. Here, we aimed to investigate the benefit of LAM treatment in infantile hepatitis B.
CASE SUMMARY
A 4-mo-old infant born to a hepatitis B surface antigen (HBsAg)-positive woman was found to be infected by HBV during a health checkup. Liver chemistry and HBV seromarker tests showed alanine aminotransferase of 106 U/L, HBsAg of 685.2 cut-off index, hepatitis B “e” antigen of 1454.0 cut-off index, and HBV DNA of > 1.0 × 109 IU/mL. LAM treatment (20 mg/d) was initiated, and after 19 mo, serum HBsAg was entirely cleared and hepatitis B surface antibody was present. The patient received LAM treatment for 2 years in total and has been followed for 3 years. During this period, serum hepatitis B surface antibody has been persistently positive, and serum HBV DNA was undetectable.
CONCLUSION
Early treatment of infantile hepatitis B with LAM could be safe and effective.
Core Tip: We report a case of infantile hepatitis B that was successfully treated with lamivudine. In addition, we review the clinical characteristics and laboratory tests and compare them with previously reported cases. Lamivudine is safe and effective in the treatment of infantile hepatitis B, and this case report may contribute to the development of relevant clinical guidelines.
